Condition: Asthma · Sponsor: Montefiore Medical Center
The objective of this study is to conduct a randomized controlled trial (RCT) to compare the adapted and refined ASTHMAXcel Voice platform to usual care (UC). It is hypothesized by the investigator team that ASTHMAXcel Voice will be associated with improved clinical and process outcomes, asthma quality of life (QOL), medication adherence, and self-efficacy as compared to UC.
This description comes directly from the study's public registry record.
Sunit Jariwala, MD · 609-937-1023 · sjariwal@montefiore.org
Juliana D Rodriguez, MD · 718-862-1722 · juliana.rodríguez@einsteinmed.edu
Always discuss trial participation with your own doctor first.
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06935084